Fasciolosis treatment with Egaten

Efficacy and safety of triclabendazole for the treatment of fasciolosis - Egaten study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs071190020

Enrollment

Registered

2019-08-13

Start date

2019-08-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fasciolosis

Interventions

Treatment with un-licensed medicine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who are diagnosed as having fasciolosis 2) Patients who give written informed consent 3) Informed consent from proxies are obtained

Exclusion criteria

Exclusion criteria: 1) Patients who are allergic to Triclabendazole 2) Patients who are pregnant, or possibly pregnant 3) Patients who does not give written informed consent 4) Patients principal investigator judged inappropriate

Design outcomes

Primary

Measure	Time frame
efficacy rate	—

Secondary

Measure	Time frame
1) Decrease in size of hepatic lesion in abdominal CT 2) Decrease in size of Parasite clearance time 3) Appearance of abdominal symptoms 4) Appearance of hepatic dysfunction 5) Appearance of skin eruption	—

Contacts

Public ContactKei Yamamoto

Japan Institute for Health Security National Center for Global Health and Medicine

yamamoto.k@jihs.go.jp+81-3-3201-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026